P

Pfizer

Makes cancer drugs, vaccines and other medicines

Representante de Salud Alta Especialidad

Full-TimePosted on 10/22/2026Deadline 11/6/26
No salary listed
Mid
Bachelor's
Remote in Mexico+1 moreMore locations: Mexico City, CDMX, Mexico
RemoteRole is 80% field and 20% virtual, with travel availability required for 50% of the time.
Sales & Account ManagementField Sales

About the job

Requirements
  • A completed licenciatura is required.
  • More than three years of experience as a medical representative or in a related position is required.
  • Intermediate English is desirable.
  • Availability to travel 50% of the time and schedule flexibility are required.
  • Practical knowledge includes interpreting clinical studies for sales, implementing marketing and positioning strategies, analyzing markets and managing audits, and basic experience in the hospital channel.
  • The role requires results orientation, decision-making, systems thinking, identifying needs and developing effective action plans, basic negotiation and judgment, effective communication, analysis and synthesis, basic strategic thinking and innovation, and basic presentation skills.
Responsibilities
  • Generate and identify business opportunities, success factors, and action plans in the assigned private and public markets through effective product promotion and collaboration with healthcare professionals, medical societies, wholesalers, purchasing decision-makers, pharmacies, laboratories, and internal colleagues to increase market share and sales results.
  • Manage assigned resources ethically and complete ongoing training and certification in sales techniques, negotiation, products, diseases, and competitors.
  • Achieve sales objectives for assigned products in the territory.
  • Propose and implement commercial tactics aligned with the needs of private and public markets and promotional activities.
  • Allocate continuing medical education resources based on territory needs and business objectives, and track return on investment.
  • Coordinate with internal and external customers on budgets and marketing and commercial strategies to plan and follow up on tactics.
  • Maintain medical, product, competitor, sales technique, negotiation, and communication knowledge; follow Pfizer policies, procedures, and values; and participate in corporate activities and initiatives.
  • Use approved sales techniques, resources, and communication channels according to each private-market customer's needs.
  • Identify and segment customers by prescribing and communication preferences, influence factors, and collaboration networks.
  • Build effective relationships with medical societies and with specialist physicians, nursing staff, laboratories, pharmacies, other healthcare professionals, and key administrators in private institutions.
  • Increase product market share and contribute to national brand objectives.
  • Analyze the territory using audit data and daily field findings, then set actions, owners, timelines, and expected results.
  • Identify and segment points of sale that affect territory results and map their connections with physicians.
  • Build effective relationships with key personnel at points of sale and develop business organization charts that include key staff, suppliers, and business timing.
  • Monitor product and competitor stock and movement, and identify prescriber performance at points of sale.
  • Maintain communication with distributor salespeople and Pfizer NAMs for each account, and ensure healthy product availability to increase or accelerate product movement.
  • Develop action plans from information gathered at points of sale, including actions, owners, and timelines.
  • Participate in Pfizer activities to include products in public-sector formularies.
  • Develop account-specific action plans based on customer and institutional needs and engage Pfizer cross-functional teams in activities that support account and institutional objectives.
  • Maximize product movement in assigned institutions to achieve sales objectives.
  • Report detected activities, behaviors, and market trends to internal teams and follow up on established action plans.
  • Build collaborative relationships and maintain communication with key institutional personnel, understand decision-making processes, and analyze available audit and other information.
  • Maintain two-way communication with NAMs, HSP, SHP, and FV contacts about institutional needs, expectations, objectives, plans, solutions, and follow-up.
  • Build effective relationships with distributors and logistics operators for assigned accounts.
  • Identify and activate new business opportunities within institutions to maximize them and contribute to product sales objectives.
Desired Qualifications
  • A specialty in medical-biological areas is desirable.
  • Intermediate English is desirable.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.